Metformina Doc (Metformin Hydrochloride)

Metformin hydrochloride reduces the liver's production of glucose and increases the sensitivity of muscle and fat cells to insulin, which enhances the uptake of glucose from the bloodstream. This dual action helps lower fasting and post‑meal blood sugar levels without directly stimulating insulin secretion.

The appropriate dose of Metformina Doc is individualized by the prescribing clinician based on factors such as the patient’s renal function, baseline glycemic control, age, and concomitant medications. The prescriber will start with a low dose and titrate upward as needed to achieve target blood glucose levels.

Metformina Doc is classified as a pregnancy‑category drug with limited data; it may be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and under close medical supervision. Breastfeeding mothers should discuss risks and benefits with their healthcare provider, as metformin does pass into breast milk in small amounts.

To place an order, submit an enquiry on the Metformina Doc product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Metformina Doc belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. Unlike insulin‑secretagogues, metformin does not cause hypoglycemia when used alone and is weight‑neutral or may promote modest weight loss. It is often used as first‑line therapy because of its efficacy, safety profile, and low cost.

Metformina Doc should be stored at ambient temperature, below 25 °C (77 °F). Keep the tablets in the original container, protect them from moisture, heat and direct sunlight, and ensure the packaging remains tightly closed until use.

Metformina Doc is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician and should not crush, chew, or split extended‑release formulations unless specifically instructed.

The most serious adverse effect is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, excessive alcohol intake, or conditions causing hypoxia. Other serious risks include severe allergic reactions such as Stevens‑Johnson syndrome and significant liver injury. Prompt medical attention is required if symptoms arise.

Metformina Doc is contraindicated in individuals with known hypersensitivity to metformin or any component of the formulation, severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in patients with severe hepatic disease. Clinicians should also exercise caution in the elderly and in those with conditions predisposing to hypoxia.